Sixty patients undergoing total hip arthroplasty were randomized to receive either fondaparinux sodium (n=30) or low-molecular-weight heparin (n=30). Outcomes of interest included the incidence of deep vein thrombosis (DVT) after surgery, Wells scores, subcutaneous ecchymosis, swelling circumference, and Visual Analogue Scale (VAS) pain scores. Outcomes were assessed at 3, 5, and 7 days postoperatively. Overall, the results of the study revealed that fondaparinux sodium was more effective than low-molecular-weight heparin in reducing the incidence of DVT, subcutaneous ecchymosis, and swelling circumference by the seventh day after surgery. The findings suggest that fondaparinux sodium may be a superior option for preventing postoperative DVT in patients undergoing total hip arthroplasty.